Overview

Phase 3 Study of Dexpramipexole in ALS

Status:
Completed

Trial end date:
2012-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of Amyotrophic Lateral Sclerosis (ALS).

Phase:

Phase 3

Details

Lead Sponsor:

Knopp Biosciences

Treatments:

Pramipexole